NAC联合BiPAP治疗OSAHS的临床疗效分析

Clinical efficacy of N-acetylcysteine combined with bilevel positive airway pressure in treatment of obstructive sleep apnea-hypopnea syndrome

目的:探讨N-乙酰半胱氨酸(NAC)联合双水平无创正压通气(Bi PAP)呼吸机治疗阻塞性睡眠呼吸暂停综合征(OSAHS)患者的临床疗效。方法:选择中重度OSAHS患者150例,随机分为三组(n=50)。12周后观察各项生化指标。结果:治疗12周后,3组患者的代谢相关指标、炎性因子指标及生活质量问卷各维度和总评得分均有显著改善(P<0.05);其中C组患者的上述各指标改善幅度优于A组和B组(P<0.05),B组患者的UA、Scr和BUN和C组患者的UA和BUN均显著高于A组患者(P<0.05)。结论:NAC治疗OSAHS安全有效,联合应用NAC和Bi PAP可提高对OSAHS的治疗效果。

Objective：To investigate the clinical efficacy of N-acetylcysteine （NAC） combined with bilevel positive airway pressure （BiPAP） in the treatment of obstructive sleep apnea-hypopnea syndrome （OSAHS）. Methods： A total of 150 patients with moderate or severe OSAHS were randomly and equally divided into three groups （groups A, B, and C）. We measured the biochemical parameters of these patients after 12 weeks of treatment. Results： After 12 weeks of treatment, the three groups showed significant improvements in metabolic parameters, inflammatory factors, and subscale and total scores of Quality of Life Questionnaire （P 〈 0.05）. Group C had significantly more improvements in the above indices than groups A and B （P 〈 0.05）. Compared with group A, group B had significantly higher levels of uric acid （UA）, serum creatinine, and blood urea nitrogen （BUN）, and group C had significantly higher levels of UA and BUN （P 〈 0.05）. Conclusions： NAC is safe and effective in the treatment of OSAHS, and has improved efficacy when used in combination with BiPAP.